×
About 2,385 results

ALLMedicine™ Burkitt Lymphoma Center

Research & Reviews  844 results

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphom...
https://clinicaltrials.gov/ct2/show/NCT04970901

Jun 24th, 2022 - This is a Phase 1b, multi-center, open-label, multi-arm study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polatuzumab vedotin, or umbralisib in participants with relapsed...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jun 24th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02911142

Jun 24th, 2022 - Background Kaposi sarcoma herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) is an aggressive B cell neoplasm with clinicopathologic and molecular profiles distinct from other AIDS-related lymphomas. There are no prospective studies on ...

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Jun 24th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Spatial distribution of incident pediatric burkitt lymphoma in central and northern mal...
https://doi.org/10.1002/pbc.29867
Pediatric Blood & Cancer; Gondwe Y, Salima A et. al.

Jun 23rd, 2022 - Burkitt lymphoma (BL) accounts for 90% of pediatric lymphomas in sub-saharan Africa. Plasmodium falciparum (Pf) malaria is considered an etiological factor of BL. We describe the geographic distribution of pediatric BL in Malawi and association wi...

see more →

Guidelines  2 results

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Clinicaltrials.gov  38 results

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphom...
https://clinicaltrials.gov/ct2/show/NCT04970901

Jun 24th, 2022 - This is a Phase 1b, multi-center, open-label, multi-arm study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polatuzumab vedotin, or umbralisib in participants with relapsed...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jun 24th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02911142

Jun 24th, 2022 - Background Kaposi sarcoma herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) is an aggressive B cell neoplasm with clinicopathologic and molecular profiles distinct from other AIDS-related lymphomas. There are no prospective studies on ...

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Jun 24th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
https://clinicaltrials.gov/ct2/show/NCT03833180

Jun 21st, 2022 - The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers includ...

see more →

News  70 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

NCCN Guidelines Set New Pace for Pediatric ALL
https://www.onclive.com/view/nccn-guidelines-set-new-pace-for-pediatric-all

Jan 3rd, 2022 - Patrick Brown, MD With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia (ALL), the National Comprehensive Cancer Network (NCCN) seeks to introduce standards to a branch of care long ...

FDA Approves Rituximab for Multiple Pediatric Cancers
https://www.medscape.com/viewarticle/964124

Dec 3rd, 2021 - The US Food and Drug Administration yesterday approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (age 6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (...

Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma
https://www.onclive.com/view/dr-noy-on-the-rationale-to-evaluate-devimistat-in-burkitt-lymphoma

Oct 6th, 2021 - Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma. Patients...

Polatuzumab Vedotin Plus R-CHP Significantly Improves PFS Over R-CHOP in DLBCL
https://www.onclive.com/view/polatuzumab-vedotin-plus-r-chp-significantly-improves-pfs-over-r-chop-in-dlbcl

Aug 10th, 2021 - Polatuzumab vedotin-piiq (Polivy) in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs ri...

see more →